Organon (OGN) Non-Current Deferred Tax Liability (2020 - 2026)

Organon (OGN) recorded quarterly Non-Current Deferred Tax Liability of $56.0 million in Q1 2026, down 1.75% quarter-over-quarter from $57.0 million in Q4 2025, and down 18.84% on a YoY basis from $69.0 million in Q1 2025.

Organon (OGN) Non-Current Deferred Tax Liability (2020 - 2026) Analysis & Trends

Organon's Non-Current Deferred Tax Liability history runs 7 years deep, the most recent figure standing at $56.0 million for Q1 2026.

  • In Q1 2026, Non-Current Deferred Tax Liability fell 18.84% year-over-year to $56.0 million; the TTM figure through Mar 2026 stood at $56.0 million (down 18.84% YoY), while the FY2025 annual figure was $57.0 million, down 65.24% from the prior year.
  • Non-Current Deferred Tax Liability was $56.0 million for Q1 2026 at Organon, down from $57.0 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $164.0 million in Q4 2024 to a low of $2.0 million in Q1 2022.
  • Historically, Non-Current Deferred Tax Liability has averaged $51.5 million across 5 years, with a median of $47.0 million in 2023.
  • The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability sank 98.4% in 2022, then surged 1400.0% in 2023.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $19.0 million in 2022, then jumped by 147.37% to $47.0 million in 2023, then soared by 248.94% to $164.0 million in 2024, then sank by 65.24% to $57.0 million in 2025, then retreated by 1.75% to $56.0 million in 2026.
  • The last three Non-Current Deferred Tax Liability figures came in at $56.0 million (Q1 2026), $57.0 million (Q4 2025), and $62.0 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,026,132.38 Bn 93,026,127.42 Bn 7.76 Bn
2 Eli Lilly 1,022.62 Bn 1,017.34 Bn 16.22 Bn
3 Johnson & Johnson 570.65 Bn 548.59 Bn 15.96 Bn
4 AbbVie 398.73 Bn 389.38 Bn 10.78 Bn
5 Merck 295.53 Bn 289.88 Bn 12.09 Bn
6 Amgen 186.30 Bn 174.26 Bn 5.87 Bn
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn
8 Pfizer 146.09 Bn 133.32 Bn -1.21 Bn
9 Bristol Myers Squibb 114.98 Bn 104.53 Bn 8.07 Bn
10 Organon 3.49 Bn 2.37 Bn 783.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 56.00 Mn
Mar 31, 2026 56.00 Mn
Dec 31, 2025 57.00 Mn
Dec 31, 2025 57.00 Mn
Sep 30, 2025 62.00 Mn
Sep 30, 2025 62.00 Mn
Jun 30, 2025 69.00 Mn
Jun 30, 2025 69.00 Mn
Mar 31, 2025 69.00 Mn
Mar 31, 2025 69.00 Mn
Dec 31, 2024 164.00 Mn
Dec 31, 2024 164.00 Mn
Sep 30, 2024 56.00 Mn
Sep 30, 2024 56.00 Mn
Jun 30, 2024 60.00 Mn
Jun 30, 2024 60.00 Mn
Mar 31, 2024 44.00 Mn
Mar 31, 2024 44.00 Mn
Dec 31, 2023 47.00 Mn
Dec 31, 2023 47.00 Mn